Question explored with the scientific record
Is there any option for hormone therapy on post menopausal women
Yes, options exist. The real question is which one, for which woman, and at what cost in risk.
Hormone therapy is a real choice for postmenopausal symptoms, not a single drug. The options differ in route and in what is combined with estrogen. Estrogen alone is used in women without a uterus; combined estrogen plus a progestogen is used to protect the uterus [2][3]. Route matters: transdermal (patch or gel) avoids the liver first pass that oral estrogen goes through, and observational data link transdermal use to lower clot and stroke risk than oral [4][5][6]. Progestogen choice also matters: a levonorgestrel intrauterine system showed no rise in breast-cell proliferation while oral norethisterone or medroxyprogesterone raised it several-fold [7].
The benefits are real but narrow. Estrogen alone lowered fracture and diabetes rates but raised stroke, clots, gallbladder disease and urinary incontinence; combined therapy lowered fracture, diabetes and colon cancer but raised invasive breast cancer, stroke, clots, incontinence and dementia, with no net benefit for preventing chronic disease in asymptomatic women [2]. Long-term observational users showed lower all-cause mortality [1], but that design cannot separate the drug from the healthy-user effect.
| Regimen | Notable benefit | Notable harm |
|---|---|---|
| Estrogen alone | Fewer fractures, less diabetes [2] | More stroke, clots, incontinence [2] |
| Estrogen + progestin | Fewer fractures, less colon cancer [2] | More breast cancer, stroke, dementia [2] |
| Transdermal estrogen | Lower clot and stroke risk vs oral [4][5] | Observational, not trial-proven [4] |
| LNG intrauterine progestogen | No breast-cell proliferation rise [7] | Small re-analysis, mixed trials [7] |
My call: for symptom relief in a woman under 60 near menopause, transdermal estrogen with a carefully chosen progestogen is a defensible option; for preventing chronic disease in an asymptomatic older woman, the answer is no. Confidence: moderate on symptom use and route differences, high that prevention is not justified.
Sources used 7
-
Reduced Mortality Associated With Long-Term Postmenopausal Estrogen Therapy
This study investigates the long-term effects of postmenopausal estrogen therapy on mortality rates, finding a significant reduction in all-cause mortality among women who used estrogen for extended periods compared to non-users.
DOI: 10.1016/0029-7844(95)00358-4 -
Hormone therapy should not be prescribed for primary prevention of chronic medical conditions in asymptomatic postmenopausal women
A USPSTF–commissioned systematic review and meta-analysis showing hormone therapy should not be used for primary prevention of chronic diseases in asymptomatic postmenopausal women, with estrogen-alone reducing some risks but increasing others and estrogen-plus-progestin increas…
DOI: 10.1136/bmjebm-2018-110930 -
Menopausal hormone therapy and cancer risks of reproductive system. Literature review
This narrative review concludes that menopausal hormone therapy's oncological risks to reproductive organs depend on regimen, progestogen type and duration, with continuous combined therapy protecting the endometrium and estrogen-only therapy raising endometrial risk.
DOI: 10.33667/2078-5631-2019-1-1(376)-42-50 -
The safety of oral versus transdermal estrogen
This Practice Pearl compares safety of oral versus transdermal estrogen, concluding that transdermal estrogen has lower VTE, stroke, and cardiovascular risk in high-risk women, while average-risk younger postmenopausal women have not shown increased risk with low-dose oral estro…
DOI: 10.1097/gme.0000000000001636 -
Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women
The ESTHER study investigates the impact of the route of estrogen administration and progestogens on the risk of venous thromboembolism (VTE) among postmenopausal women, finding that oral estrogen increases VTE risk while transdermal estrogen does not, and that certain progestog…
DOI: 10.1161/CIRCULATIONAHA.106.642280 -
Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone
This study reviews the cardiovascular risks associated with different hormone replacement therapy (HRT) regimens in postmenopausal women, highlighting the safety of transdermal estradiol compared to oral estrogens.
DOI: 10.3109/13697137.2012.669624 -
Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate
E2V with a low-dose levonorgestrel intrauterine system gave no increase in normal breast epithelial proliferation, unlike oral estradiol/NETA or CEE/MPA which increased proliferation 4-7-fold.
DOI: 10.1515/hmbci-2019-0051